DAT Scanning an Effective Tool for Identifying Prodromal PD in RBD

EMBARGOED until Wednesday, June 17, 2015
Media Contact:

Elizabeth Clausen, +1 414-276-2145, eclausen@movementdisorders.org

PPMI Researchers Find DAT Scanning to be an Effective Tool for Identifying Prodromal Parkinson’s Disease in REM Sleep Behavior Disorder

SAN DIEGO – Researchers with the Parkinson Progression Marker Initiative (PPMI) have found that dopamine transporter (DAT) scanning can be an effective tool in identifying prodromal Parkinson’s disease (PD) in REM sleep behavior disorder (RBD), according to a study released today at the 19th International Congress of Parkinson’s Disease and Movement Disorders. The PPMI aims to identify one or more biomarkers of Parkinson’s disease progression, which is a crucial step in research and development of new and improved treatments for Parkinson’s disease (PD).

This study evaluated a cohort of prodromal subjects within the PPMI with RBD and dopamine transporter (DAT) deficit to examine the biomarkers in the earliest stages of PD. Several studies have already shown that RBD is a substantial risk factor for the development of PD, but this study found that approximately 50% of subjects, identified by sleep studies and clinical criteria as those with RBD, showed a DAT deficit.

Ron Postuma, Associate Professor at Montreal General Hospital states, “Long-term studies have now definitively shown that most patients with idiopathic RBD are in fact in early (prodromal) stages of neurodegenerative disease. This study shows that this prodromal status can be demonstrated with DAT scanning. It will be extremely interesting to watch how these patients evolve over time, both to see how the DAT deficit progresses, and how strongly it can predict when a patient with prodromal disease converts to full clinical disease.” Postuma adds, “Finally, this study illustrates that patients like this represent the ideal candidate population for a neuroprotective trial against PD and DLB.”

About the 19th International Congress of Parkinson's Disease and Movement Disorders:
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson's disease. Over 3,500 physicians and medical professionals from more than 80 countries will be able to view over 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society:
The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.